Such findings are illustrative of how the effects of fibulin-3 in cancer more generally occur via diverse actions on numerous cell types within the tumour microenvironment, adding an additional layer of complexity to its signalling functionality. This evidence concerns the gene EFEMP1 and neoplasm.